Kernal Bio presents at the Bio€quity Europe
CAMBRIDGE, Mass., May 13, 2025
Kernal Bio, a venture-backed biotech company developing mRNA 2.0 immunotherapies, announced today that CEO Yusuf Erkul, M.D., M.B.A, will present the company's mRNA platform and pipeline at the Bio€quity Europe 2025 Conference in Belgium on Tuesday, May 13, 2025, at 3:45 p.m. CET.
Celebrating its 25th year, Bio€quity Europe is the destination event for biopharma for C-suite executives, biopharma leaders, dealmakers, venture capitalists, private investors and policymakers to network, partner and debate critical issues facing the biotech industry.
About Kernal Biologics, Inc.
Kernal Bio is pioneering the engineering of human cells inside the body using selective mRNA-LNP technology to fight autoimmune diseases and cancer. By delivering antibody-decorated lipid nanoparticles (LNPs) that precisely target specific cell types, AI-designed mRNAs ensure high specificity and minimize off-target effects within the body. Kernal Bio has demonstrated remarkably high in vivo delivery efficiency (>90%) with our T-cell-targeted mRNA LNPs. Recently, by deploying these for in situ CAR-T programming, the company achieved successful in vivo B-cell killing. KR-402 program is being developed for hematological malignancies and autoimmune disorders. The cancer cell-targeting program, KR-335, boasts a 100x therapeutic index, showing high efficacy in solid tumors resistant to conventional immuno-oncology agents. It demonstrated strong tolerability in preclinical models, including mice and non-human primates.
With roots in MIT, Harvard, Merck, and BMS, the management team has led the way with three FDA-approved therapies and 120+ patents. Based in Cambridge, MA, and backed by investors like Hummingbird Ventures, Amgen Ventures, and HBM, Kernal Bio is revolutionizing mRNA therapeutics by harnessing AI to direct precision treatments within the body.
Please visit our website at www.kernalbio.com and on social media: Facebook, X, and LinkedIn.
About the mRNA2.0 Platform
Kernal Bio is at the forefront of mRNA therapeutics and synergistically exploits targeted LNP (lipid nanoparticle) delivery and cell-selective translation of its synthetic mRNA, controlling the amount and site of protein produced, without the need for any genetic editing or the risk of genomic integration. Our proprietary best-in-class decorated lipid nanoparticle technology allows us to achieve in situ cell engineering via systemic, targeted, extra-hepatic delivery to specific tissues and cells, such as T cells. The delivery capability, combined with the translation of cell-selective mRNA, eliminates off-target effects. This expertise is enabled by Kernal Bio’s proprietary machine learning (ML) powered platform that discovers RNA sequence motifs from clinical human data with preferential translation based on cell type.